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ABBREVIATIONS
Aa amino acid(s)
AMP adenosine monophosphate
AMPK AMP activated protein kinase
ARNT aryl hydrocarbon receptor nuclear translocator
ATP adenosine triphosphate
BMP bone morphogenetic protein
CaMK calmodulin-dependent protein kinase
cAMP cyclic adenosine 3´, 5´-monophosphate
cDNA complementary deoxyribonucleic acid
CD Cowden Disease
CGH comparative genomic hybridization
CMV Cytomegalo Virus
CNS central nervous system
C-terminus carboxy terminus
DAB 3,3'-diaminobenzidine
DNA deoxyribonucleic acid
DMEM Dulbecco´s modified Eagle´s medium
E embryonic day
EBV Epstein-Barr Virus
ELISA enzyme-linked immunosorbent assay
ES embryonic stem cell
FACS fluorescence-activated cell sorter
FCS fetal calf serum
FITC fluorescein isothiocyanate
flk-1 fetal liver kinase 1 (VEGF receptor 2)
flt-1 fms-like tyrosine kinase 1 (VEGF receptor 1)
HA hemagglutinin
HIF-1 hypoxia inducible factor-1
HSV Herpes Simplex Virus
Ig immunoglobulin
IU international unit
JP Juvenile Polyposis
kb kilobase
kDa kilodalton
LOH Loss of heterozygosity
MEF mouse embryonic fibroblasts
mRNA messenger ribonucleic acid
N-terminus amino terminus
ORF open reading frame
PCR polymerase chain reaction
PI-3’-kinase phosphatidyl inositol 3 ’-kinase
PJS Peutz-Jeghers syndrome
PKA protein kinase A
PKB protein kinase B/Akt
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p53 p53 tumor suppressor (transcription factor)
p16 p16 tumor suppressor (cyclin dependent kinase inhibitor)
RNA ribonucleic acid
RT-PCR reverse transcriptase polymerase chain reaction
SCTAT sex cord tumor with annular tubules
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SMAD4 cytoplasmic mediator of TGF-ß and BMP signaling
SMC smooth muscle cell
tk thymidine kinase
TUNEL terminal deoxynucleotidyl transferase–mediated dUTP nick
end-labeling (apoptosis detection)
VEGF vascular endothelial growth factor
VHL von Hippel-Lindau tumor suppressor
Xeek1 Xenopus egg and embryo kinase-1
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ABSTRACT
Cancer is considered a disease of the
genome triggered by environmental
factors. Most cancers occur sporadically
without an apparent family history, but
inherited cancer susceptibility syndromes
are thought to account for 1-2% of cases.
Recent advances in human genetics have
revealed multiple tumor suppressor genes
that underlie inherited cancer syndromes.
Although these syndromes are rare
conditions, tumor suppressor genes play a
key role also in the development of
sporadic cancers.
Peutz-Jeghers syndrome is an inherited
disease characterized by pigmentation of
the mucous membranes, hamartomatous
polyps in the gastrointestinal tract and an
elevated risk of cancer. The cancers affect
a variety of organs, but especially high
risk has been demonstrated for
gastrointestinal malignancies and
pancreatic carcinoma.
Peutz-Jeghers syndrome is caused by
germline mutations in the LKB1
serine/threonine kinase gene. Most serine
/threonine kinases are intracellular
proteins that typically form signal
transduction cascades translating various
signals into a coordinated transcriptional
response in the nucleus. While LKB1
mutations are found in Peutz-Jeghers
syndrome the mechanism how these
mutations predispose to cancer is not
known.
In this study we have demonstrated
that LKB1 gene mutations in Peutz-
Jeghers syndrome disrupt Lkb1 kinase
activity. We also show that LKB1 mRNA
expression and Lkb1 kinase activity are
downregulated in tumor cell lines
suggesting that LKB1 mRNA
downregulation is a mechanism to
inactivate Lkb1 function in cancer. We
have also demonstrated that Lkb1 kinase
activity inhibits cell proliferation by
inducing a G1 cell cycle arrest. Therefore,
demonstrating that LKB1 is a gatekeeper
gene directly controlling cell proliferation.
To study the in vivo functions of Lkb1
kinase we have generated mice lacking
Lkb1. Mice lacking Lkb1 die during
midgestation, thus demonstrating that
Lkb1 is essential for mammalian
development. Moreover, severe vascular
abnormalities were observed in embryonic
and extraembryonic compartments and in
further studies the vascular endothelial
growth factor VEGF mRNA expression
was shown to be deregulated in both
compartments. VEGF expression was also
shown to be upregulated in fibroblasts
d rived from the Lkb1 mutant embryos
thereby placing Lkb1 in the VEGF
signaling pathway.
This study has demonstrated that Lkb1
regulates both cell proliferation and
angiogenesis, both of which are key steps
in cancer development. Finally, this study
may provide a rationale for the increased
risk of cancer incidence among Peutz-
Jeghers syndrome patients and helps to
evelop novel cancer therapies based on
the identified mechanisms.
Introduction
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INTRODUCTION
Cancer is a Disease
of the Genome
Cancer is one of the leading causes of
morbidity and mortality in developed
societies (Peto, 2001). Epidemiological
studies have shown that smoking, diet,
radiation and certain virus infections
increase cancer risk. Many of these risk
factors contain chemical carcinogens or
physical agents capable of damaging DNA
resulting in genomic lesions. Thus, cancer
is considered a disease of the genome
triggered by environmental factors.
Although most cancers occur sporadically
without an apparent family history, up to
10% of cancers are thought to have
familial predisposition. Rare inherited
cancer susceptibility syndromes account
only for 1-2% of cases. However, similar
genetic alterations have also been
suggested to play critical role in common
sporadic cancers.
Genes in Cancer Development
Cancer is a disease characterized by
clonal expansion of cells that
progressively shift from normal cells to
invasive cancer cells via intermediate
steps (Fearon and Vogelstein, 1990). Cells
require certain characteristics to adopt
malignant phenotype. This multistep
process requires alterations in the function
of many genes.
Genes involved in the development of
cancer are commonly divided into
oncogenes and tumor suppressors. Both
groups control key cellular properties
required for cancer development. These
p operties can be grouped into six separate
characteristics including sustained positive
growth signaling, insensitivity to negative
growth signaling, tissue invasion, cell
immortalization, induction of
angiogenesis and evasion from
programmed cell death (Table1) (Hanahan
and Weinberg, 2000). Each genetic event,
which either activates oncogenes or
inactivates tumor suppressors gives cells a
growth advantage over normal cell
population and leads to sequential
conversion of normal cells into cancer
cells.
Table 1. Characteristics of malignant cells (Hanahan and Weinberg 2001)
List of key characteristics that normal cells have to adopt to become malignant and
capable of developing metastatic cancer.
Self-sufficiency in growth signaling
Insensitivity to anti-growth signaling
Tissue invasion and metastasis
Limitless replicative potential
Sustained angiogenesis
Evasion of apoptosis
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Oncogenes
The first oncogenes (e.g. src, Ha-ras)
were originally discovered in the DNA of
retrovirus genomes having the capacity to
induce malignant transformation of
cultured cells. Subsequently, the same
oncogenes were found also in human
cancer cells (Bishop, 1981) (Parada et al.,
1982). Surprisingly, even normal cells
were reported to carry genes that were
related to oncogenes. These genes were
termed proto-oncogenes to distinguish
them from oncogenes found in viruses and
cancer cells. Proto-oncogenes were found
to have an important function in normal
cell signaling regulating cell growth and
differentiation (Cantley et al., 1991).
However, proto-oncogenes could become
cancerous oncogenes by genomic
alterations enhancing their function.
In fact, gain-of function mutations,
over-expression, chromosomal
translocations and gene amplifications of
proto-oncogenes are frequently observed
in human neoplasia (Bishop, 1991).
Tumor Suppressors
The first evidence for the presence of
tumor suppressor genes came from
epidemiological studies of the familial and
non-familial forms of a rare ocular tumor -
retinoblastoma. Knudson proposed that
both copies of a given tumor suppressor
gene are inactivated in cancer (Knudson,
1971). This “two-hit” hypothesis
suggested that familial retinoblastoma
patients had inherited one defective allele
of a gene predisposing to retinoblastoma.
The other allele of this gene would then be
somatically mutated leading to tumor
development. In the non-familial cases
both alleles had to be somatically
inactivated demanding more time. This
explained the later occurrence of
retinoblastoma in sporadic cases. Later,
the Rb gene was identified and mutations
in both alleles of this gene were reported
in retinoblastomas, supporting the
Knudsons hypothesis (Lee et al., 1987).
Gatekeepers and Caretakers
Tumor suppressors can be further
divided into gatekeepers and caretakers
based on gene function (Kinzler and
Vogelstein, 1997). Gatekeepers prevent
neoplasia directly by controlling cell
growth, either by regulating proliferation
or by promoting cell death. Although
multiple gatekeeper genes have been
identified, only one gatekeeper is thought
to be active in a given cell type and
inactivation of this gatekeeper is rate
limiting for tumor development. Thus,
when both alleles of a gatekeeper gene are
inactivated in target tissue, cells escape
from normal growth control.
In contrast, caretaker genes prevent
malignant transformation indirectly by
maintaining genomic integrity. This class
of tumor suppressors contains genes
involved in DNA repair and replication.
Mutations in caretaker genes result in
genomic instability and in increased
utation rate. Consequently, gatekeepers
are prone to become inactivated and
oncogenes activated due to the genomic
instability.
Landscaper genes have been suggested
to be a third category of tumor
suppressors, in which the genetic defect is
not in the neoplastic cell population itself
but rather in the adjacent stromal cells. As
a result, cells associated with the abnormal
stroma develop malignancy due to an
abnormal intercellular signaling (Kinzler
and Vogelstein, 1998).
Review of the Literature
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REVIEW OF THE
LITERATURE
1. Cancer Syndromes are
Caused by Tumor
Suppressor Gene Mutations
Linkage studies and positional cloning
have revealed multiple tumor suppressor
genes that underlie inherited cancer
syndromes (Table 2). Although inherited
cancer syndromes are rare conditions,
tumor suppressor gene inactivation has a
major role also in the development of
sporadic cancers (Weinberg, 1995).
According to Knudson´s “two hit”
model tumor development requires
inactivation of both alleles of a tumor
suppressor gene (Knudson, 1971). Indeed,
loss of heterozygosity (LOH) of a tumor
suppressor gene is frequently detected in
cancers. However, some recent reports
suggest that haploinsufficiency caused by
losing only one tumor suppressor allele is
sufficient for tumor development (Fero et
al., 1998; Roberts et al., 2000; Smits et al.,
2000; Wetmore et al., 2000; Xu et al.,
2000; Zurawel et al., 2000).
In addition to inactivating mutations in
tumor suppressors, some cancer
syndromes arise due to activating
mutations in proto-oncogenes. A
particularly interesting mechanism
underlies familial melanoma, where
mutations in CDK4 gene render cell cycle
regulator cdk4 (cyclin dependent kinase 4)
resistant to its inhibitors thus increasing
cdk4 activity and promoting cell division
(FitzGerald et al., 1996; Whelan et al.,
1995).
Table 2. Cancer syndromes caused by tumor suppressor mutations
A list of cancer syndromes that are caused by inactivating mutations in tumor suppressor
genes. Proposed category indicates whether the tumor suppressor gene has a caretaker or
a gatekeeper function.
Disease Affected gene Protein function Proposed
category
Tumor spectrum in
affected patients
Ataxia-telangiectasia ATM
Protein kinase, maintains
genomic integrity Caretaker
Breast cancer,
leukemia and
lymphoma
Bannayan-Riley-
Ruvalcaba syndrome
PTEN
Phosphatase that inhibit PI 3-
kinase –Akt pathway. Regulates
cell cycle, aopotosis and
angiogenesis
Gatekeeper
Breast and thyroid
cancer, intestinal
hamartomas
Basal cell nevus PTCH
Receptor for sonic hedgehog
pathway Gatekeeper
Basal cell
carcinoma,
medulloblastoma
Bloom´s syndrome BLM
DNA helicase, maintains
genomic integrity Caretaker
Leukemias,
lymphomas and
multiple carcinomas
Review of the Literature
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Carney complex PRKAR1A
Protein kinase A regulatory
subunit Unknown
Cardiac and other
myxomas, endocrine
tumors and
melanotic
schwannomas.
Cockayne syndrome XPB, XPD and
XPG
Required for DNA excision
repair
Caretaker Melanoma, basal
cell carcinoma
Cowden syndrome
(CS),
PTEN
Phosphatase that inhibit PI 3-
kinase –Akt pathway. Regulates
cell cycle, aopotosis and
angiogenesis
Gatekeeper
Breast and thyroid
cancer, intestinal
hamartomas
Familial
Adenomatous
Polyposis (FAP)
APC
Sequesters ß-Catenin in the
cytoplasm Gatekeeper
Cancer in GI-tract,
osteomas,
medulloblastoma
Familial breast and
ovarian cancer
BRCA1, BRCA2
Maintains genomic integrity by
repairing DNA doublestrand
breaks
Caretaker
Breast and ovarian
cancers, BRCA2
also in pancreatic
and prostate cancer
Familial gastric
cancer
E-Cadherin Interacts with ß-Catenin and
regulates cell adhesion
Gatekeeper Gastric cancer
Familial
melanoma/dysplastic
nevus
CDKN2 (P14,
p16, p19ARF)
p14 and p16 are CDK inhibitors,
block cell cycle, p19ARF
regulates p53 via  MDM2
Gatekeeper
Melanoma,
pancreatic, bladder
and esophageal
cancer, leukemia
Fanconi anemia
FANCA,
FANCC,FANC
D, FANCE,
FANCF,
FANCG
Maintain genomic integrity Caretaker
Leukemia and
squamous cell
carcinomas
Hereditary Non-
Polyposis Colorectal
Carcinoma (HNPCC)
MSH2, MSH3,
MSH6, PMS1,
PMS2, MLH1
DNA mismatch repair Caretaker
Colorectal, gastric,
endometrial,
ovarian,
hepatobiliary and
urinary tract
cancers,
glioblastoma
Li Fraumeni p53
Transcription factor, Regulates
cell cycle, apoptosis and
angiogenesis.
Gatekeeper
Multiple sarcomas,
brain tumors, breast
cancer, leukemia
Multiple endocrine
neoplasia type I
MENI
Interacts with the AP-1
transcription factor JunD and
represses JunD-activated
transcription
Unknown
Gastrinoma,
insulinoma,
parathyroid tumors
Multiple exostoses EXT1, EXT2,
EXT3
Heparan sulfate polymerase
activity
Unknown Exostoses,
chondrosarcoma
Nijmegen breakage
syndrome NBS1
Maintains genomic integrity by
repairing DNA doublestrand
breaks
Caretaker Lymphomas
Neurofibromatosis NF1,NF2
Regulates Ras signaling and
cytoskeleton Gatekeeper
Neurofibromas,
gliomas,
astrocytomas,
meningeomas,
scwannomas
Paraganglioma SDHD Small subunit of cytochrome b in
mitochondrial complex II
Unknown Nonchromaffin
paragangliomas
Peutz-Jeghers
syndrome (PJS) LKB1
Serine/threonine kinase.
Angiogenesis and cell cycle
regulation
Gatekeeper
Cancer in GI-tract,
pancreas, breast,
ovary and testis
Retinoblastoma Rb Cell cycle control Gatekeeper Retinoblastoma,
osteosarcoma
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Rothmund-Thomson
syndrome
RECQ4 DNA helicase, maintains
genomic integrity
Caretaker Osteosarcoma
Tuberous sclerosis
TSC1,
TSC2
Regulates cell proliferation,
growth and adhesion via small
GTPases
Gatekeeper
Renal cell
carcinoma,
angiomyolipoma,
astrocytoma,
hamartomas
Werner syndrome WRN
DNA helicase and exonuclease
maintaining genomic integrityCaretaker
Soft tissue
sarcomas,
meningeomas,
thyroid carcinomas,
melanomas
Willms tumor WT1 Zinc finger transcription factor
with multiple target genes
Gatekeeper Nefroblastoma
von Hippel-Lindau VHL
Component of ubiquitin-ligase
complex, regulates cell cycle,
adhesion and angiogenesis
Gatekeeper
Clear renal cell
carcinoma,
feochromocytomas,
hemangioblastomas,
colorectal cancer
Xeroderma
pigmentosum
XPA, XPB,
XPC, XPD,
XPE, XPF, XPG
DNA excision repair Caretaker
Melanoma, basal
cell carcinoma
Review of the Literature
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2. Peutz-Jeghers Syndrome
(PJS)
Peutz-Jeghers syndrome (PJS) is an
autosomally dominantly inherited disease
characterized by pigmentation of the
mucous membranes, hamartomatous
polyps in the gastrointestinal tract and an
elevated risk of cancer (Hemminki, 1999;
Tomlinson and Houston, 1998).
The first two patients with signs of PJS
were described in the late 19th century.
One died of small bowel obstruction and
the other developed breast cancer
(Hutchinson, 1896). Later, Peutz
described a family with a history of
polyposis and aberrant mucocutaneous
pigmentation (Peutz, 1921) and in 1940s
Jeghers reported observations of 12
patients with polyposis and pigmentation
linking them together as a clinical entity
(Jeghers 1944, 1949).
The incidence of PJS has been
estimated to be between 1:8300 to
1:29000 live births (Finan and Ray, 1989;
Mallory and Stough, 1987), but some
investigators have estimated it to be less
common (Spiegelman, 1994; Hemminki,
1999). Peutz-Jeghers patients commonly
have a family history of polyposis and
pigmentation, but 10-20% of cases lack an
apparent family history and are caused by
sporadic de novo mutations. Reliable
cases of incomplete penetrance have not
been reported suggesting a complete
penetrance of PJS (Amos et al., 1997;
Hemminki et al., 1997; Mehenni et al.,
1997; Nakagawa et al., 1998).
2.1 Symptoms of PJS
The earliest presenting sign of PJS is
the characteristic pigmentation of the oral
area, buccal mucosa, vulva, fingers and
toes. The pigmentation is commonly first
noted on the lower lip. The vast majority
of PJS patients exhibit pigment macules,
but marked differences in localization and
intensity between patients and families has
been documented (Westerman, 1997). In
older age, pigmentation may diminish or
ven disappear. The mechanism of the
pigmentation is poorly understood,
lthough one electron microscopic study
demonstrates a block in the melanosome
transfer from the melanocytes to
keratinocytes suggesting melanocyte
dysfunction (Yamada et al., 1981).
In addition to the pigment macules the
symptoms caused by gastrointestinal
polyposis can lead to the diagnosis of PJS.
The polyps commonly cause occlusion,
intussusception, abdominal pain, bleeding
and a prolapse of a rectal polyp (Burdick
and Prior, 1982; Foley et al., 1988;
Utsunomiya et al., 1975). The majority of
cases are diagnosed before the 3rd decade
of life (Utsunomiya et al., 1975), but in
some patients the polyposis causes only
mild symptoms and the disease manifests
in old age (Laughlin, 1991).
2.2 Polyposis in PJS
Gastrointestinal polyps are commonly
classified into adenomatous, hyperplastic,
and hamartomatous polyps. Adenomatous
polyps are masses of mucosal epithelium
originating from aberrant proliferation in
intestinal crypts. The majority of
colorectal cancers develop stepwise from
pre-existing adenomatous polyps, thus
establishing adenomas as premalignant
lesions (Fearon and Vogelstein, 1990;
Vogelstein and Kinzler, 1993).
Hyperplastic polyps are histologically
well-differentiated polypoid mucosal
protrusions, but progression to cancer is
less common than in adenomatous polyps
(Daibo et al., 1987; Jass et al., 1992).
Hamartomatous polyps consist of
multiple well-differentiated tissues
Review of the Literature
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endogenous to the site of polyp.
Originally, hamartomas were thought to
be benign lesions, but recent studies have
indicated that hamartomas may progress
to carcinoma via intermediate steps
mimicking the stepwise transformation of
adenoma to carcinoma (De Facq et al.,
1995; Defago et al., 1996; Entius et al.,
1997; Gruber et al., 1998; Hizawa et al.,
1993; Perzin and Bridge, 1982; Spigelman
et al., 1989).
The diagnostic feature of PJS is the
development of specific hamartomatous
polyps in the gastrointestinal tract. PJS-
associated hamartomatous polyps are
pedunculated, usually relatively large, and
often cystic. Macroscopically they may
resemble adenomas. Polyps are frequently
found in small intestine (70-90%) of the
patients, but they can also be detected in
colon and rectum (50%) and in stomach
(25%) (Burdick and Prior, 1982; Foley et
al., 1988; Utsunomiya et al., 1975). In
addition to the gastrointestinal tract,
hamartomatous polyps have occasionally
been reported in nasal and oral cavities,
esophagus, in respiratory and urinary
tracts and in breasts in PJS patients.
(Burdick and Prior, 1982; De Facq et al.,
1995; Jancu, 1971; Keating et al., 1987;
Sommerhaug and Mason, 1970).
Histologically PJS polyps are
characterized by well differentiated, but
dysorganized glandular epithelium with
numerous clear goblet cells (Rosai, 1996).
A diagnostic feature of the hamartomatous
polyps in PJS is a dominant, well-
developed smooth muscle component
originating from the polyp stalk. This
smooth muscle infiltration can be
observed even in the periphery of the
polyp by immunohistochemistry with
antibodies against smooth muscle actin
and desmin (Fulcheri et al., 1991). In
addition to hamartomatous polyps,
hyperplastic and adenomatous polyps are
occasionally detected in PJS patients.
2.3 Increased Risk of Cancer in
PJS
Early studies of PJS failed to
demonstrate increased cancer risk among
PJS patients. A study of 21 PJS cases
concluded that malignant transformation
of hamartomatous polyps rarely occurs
(Dormandy, 1957). Similarly, a 10-year
follow-up of a large PJS family did not
provide evidence for an increased cancer
incidence in PJS (Burdick et al., 1963).
However, 19 years later after a 27-year
follow-up, two breast cancers, one jejunal
adenocarcinoma arising from a polyp and
three benign ovarian tumors were detected
in the same family. (Burdick and Prior,
1982).
The first evidence of the increased
cancer incidence in PJS patients came
from a study, which reported four gastric,
three duodenal, one ileal and three
colorectal cancers in 321 PJS patients
(Dozois et al., 1969). Later, 28 cancers
and increased mortality were reported in a
large study of 222 Japanese PJS patients
(Utsunomiya et al., 1975). However, a 33-
year follow-up study of 48 PJS patients
detected only one gastrointestinal cancer
and failed to demonstrate decreased
survival questioning the possible
premalignant potential of PJS (Linos et
al., 1981).
The most convincing evidence
supporting the increased risk of cancer in
PJS came from a 12-year follow-up of 31
familial PJS patients. Fifteen
histologically verified cancers were
reported including four gastrointestinal
carcinomas, ten non-gastrointestinal
carcinomas and one myeloma (Giardiello
et al., 1987). The cancer risk was
estimated 18-fold higher than in general
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population. Moreover, Boardman et al.
have suggested that female PJS patients
are at even higher risk than male patients
due to particularly high risk of breast and
gynecologic cancers (Boardman et al.,
1998).
A recent meta-analysis has
summarized data collected from six
publications including 210 patients. The
relative risk of all cancers among PJS
patients was estimated 15.2 fold higher
than in general population and the
cumulative risk of developing malignancy
by the age of 64 was 94% (Giardiello et
al., 2000). The relative risks calculated for
individual types of cancers presented in
Table 3 demonstrate high relative risk for
gastrointestinal and pancreatic cancers.
The high cumulative risk of ovarian,
uterine and breast cancers suggests that
female PJS patients are at higher risk of
developing malignancy than men.
Table 3. The incidence of cancer in PJS Patients (Giardello et al., 2000)
The meta-analysis included data from publications where all PJS diagnoses were based on typical
clinical and histopathologic findings. The cancer diagnoses were also confirmed by histology.
Malignancies were most commonly seen in breast, colon, pancreas and stomach. There was
especially high relative risk for developing small intestinal cancer, which otherwise is a rare
malignancy.
Carcinoma Number of
cases
reported
Relative risk
(Observed/Exp
ected)
Cumulative
risk from age
15 to 64
Small intestine 6 520 13%
Stomach 10 213 29%
Pancreas 6 132 36%
Colon 15 84 39%
Esophagus 1 57 0.5%
Ovary 4 27 21%
Lung 5 17 15%
Uterus 2 16.0 9%
Breast 11 15.2 54%
Testes 1 4.5 * 9%
Cervix** 3 1.5 * 10%
All cases 66 15.2 93%
*) statistically not significant **) Most cases of adenoma malignum not included
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2.4 Characteristic Ovarian and
Uterine Tumors in PJS
Sex-cord tumor with annular tubules
(SCTAT) is a rare benign neoplasm
almost exclusively seen in PJS patients.
SCTAT tumor is commonly calcified,
small, multifocal and bilateral.
Histologically it has features of granulosa
cell and sertoli cell tumor and focal
differentiation of both cell types may
occur. Occasionally, these tumors are
hormonally active resulting in symptoms
associated with hyperestrogenism
(Herruzo et al., 1990; Scully, 1970; Young
et al., 1983; Young et al., 1982).
Adenoma malignum or minimal
deviation adenocarcinoma is a rare well-
differentiated form of cervical
adenocarcinoma seen in PJS patients. It
has been estimated that 10% of all
adenoma malignum cases occur in PJS
patients (Gilks et al., 1989; Szyfelbein et
al., 1984) and that it commonly co-exists
with ovarian tumors (Srivatsa et al., 1994;
Young and Scully, 1988).
2.5 Polyposis Syndromes
Related to PJS
Cowden disease (CD) and Juvenile
polyposis (JP) are dominantly inherited
polyposis syndromes similar to Peutz-
Jeghers syndrome, which exhibit genetic
heterogeneity. PJS is distinguished from
these syndromes by the extensive
infiltration of smooth muscle in the
polyps.
Patients with Cowden disease exhibit
cutaneous hamartomas and
trichilemmomas, hamartomatous polyps in
gastrointestinal tract and increased risk of
breast, thyroid and skin cancer (Hanssen
and Fryns, 1995; Weinstock and
Kawanishi, 1978). Mutations in PTEN
gene have been shown to underlie
Cowden disease (Liaw et al., 1997; Lynch
et al., 1997; Nelen et al., 1997). PTEN
gene encodes for a phosphatase that
regulates negatively the PI3'K/PKB/Akt
signaling pathway by dephosphorylating
phosphoinositoles (Maehama and Dixon,
1998; Myers et al., 1998; Stambolic et al.,
1998). One study suggests that PTEN also
dephosphorylates focal adhesion kinase
(FAK) regulating cell adhesion and
motility (Tamura et al., 1998), but the
tumor suppressive function of PTEN has
been shown to be dependent only on its
lipid phosphatase activity (Myers et al.,
1998)
Juvenile polyposis (JP) is characterized
by distinct type of hamartomatous polyps
in the colon (Desai et al., 1995).
Occasionally adenomatous and mixed
histology polyps are found in JP patients.
Histologically the polyps exhibit dilated
glandular structures lined by mucus
secreting epithelium with thick lamina
propria. Although juvenile polyps rarely
undergo malignant transformation,
patients with JP are at higher risk of
gastrointestinal cancer (Giardiello et al.,
1991; Giardiello and Offerhaus, 1995;
Jarvinen and Franssila, 1984; Sassatelli et
al., 1993). JP is caused by mutations in
SMAD4, BMPR1 and PTEN genes
demonstrating genetic heterogeneity
between these cancer syndromes (Howe et
al., 2001; Howe et al., 1998; Olschwang et
al., 1998). BMPR1 encodes for a bone
morphogenetic protein receptor 1, and
SMAD4 for a cytoplasmic mediator of the
bone morphogenetic protein and
ransforming growth factor-beta signaling.
This suggests that the BMP signaling
pathway is involved in the pathogenesis of
JP.
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3.Mutations in LKB1 Gene
Underlie PJS
3.1 PJS locus and LKB1 gene
The PJS susceptibility locus was
identified by assuming that hamartomas
are clonal expansions that exhibit loss of
heterozygosity (LOH) according to
Knudson´s “two-hit” model. Indeed, small
chromosomal deletions were found in the
short arm of chromosome 19 by
comparative genomic hybridization
(CGH) followed by demonstration of
linkage to 19p13.3 (Hemminki et al.,
1997). Other groups confirmed this
finding (Amos et al., 1997; Nakagawa et
al., 1998). In addition, Olschwang et al.
reported three families, and Mehenni et al.
one family, that were not linked to
19p13.3, suggesting the presence of
another PJS locus (Mehenni et al., 1997;
Olschwang et al., 1998). Furthermore,
Mehenni et al. demonstrated linkage to
alternative locus at 19q13.4 in a large
Indian family that did not show linkage to
19p13.3 (Mehenni et al., 1997).
Subsequently, germline mutations were
identified in PJS patients in LKB1
(STK11) serine/threonine kinase gene
located in 19p13.3 region (Hemminki et
al., 1998; Jenne et al., 1998). LKB1 gene
consists of 10 exons, the first being
partially coding, and 10th exon non-
coding. The LKB1 mRNA is ubiquitously
expressed, but particularly high expression
has been reported in testis and fetal liver
(Hemminki et al., 1998; Jenne et al.,
1998).
3.2 Germline Mutations in PJS
Surprisingly, considerable variation in
the LKB1 mutation frequency has been
reported. The first reports detected
germline LKB1 mutations in vast majority
of PJS patients (Gruber et al., 1998;
Hemminki et al., 1998; Jenne et al., 1998).
Later studies, however, have found coding
region or splice mutations only in 55% to
77% of PJS patients (Mehenni et al., 1998;
Nakagawa et al., 1998; Olschwang et al.,
2001; Resta et al., 1998; Wang et al.,
1999; Westerman et al., 1999; Ylikorkala
et al., 1999). Some studies have suggested
that LKB1 mutations are even more
uncommon (Boardman et al., 2000; Jiang
et al., 1999; Yoon et al., 2000). However,
it is likely that these studies have
underestimated the LKB1 mutation
frequency due to low sensitivity mutation
screening methods.
The majority of LKB1 mutations are
small deletions or point mutations
predicted to truncate Lkb1 protein and
compromise its function, but many
mutations cause only single amino acid
substitutions, small in-frame deletions or
minor truncations (Figure 1).
3.3 LKB1 Mutations in PJS
Polyps
In addition to the chromosomal losses
in CGH analysis, Hemminki et al.
demonstrated LOH near the LKB1 locus
by PCR in three PJS polyps. LOH was
found to be restricted to areas having high
number of clear goblet cells suggesting
that they might be the primary clonal
neoplastic cell population. No allelic
imbalance was detected in the stromal
tissues of the polyps suggesting that the
smooth muscle hyperproliferation in PJS
polyps is not a clonal event. (Hemminki et
al., 1997). Other studies have reported
variable frequencies of LOH in the PJS
polyps. While Gruber et al. demonstrated
LOH by PCR in majority of polyps
(Gruber et al., 1998). Entius and Miyaki
suggested that LOH of LKB1 might be
less frequent in PJS polyps (Entius et al.,
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2001; Miyaki et al., 2000). Alternatively,
promoter methylation or small missense
mutations, could be responsible for
inactivating LKB1. Interestingly, Rowan
studied LOH negative PJS polyp by in situ
hybridization and demonstrated LKB1
mRNA expression throughout the polyp,
suggesting that some polyps retain LKB1
mRNA expression (Rowan et al., 2000).
This is supported by our data showing that
LKB1 mRNA and protein expression and
kinase activity are not compromised in
hamartomatous polyps arising in mice
modeling PJS (Rossi et al., unpublished).
The molecular analysis of carcinomas
in PJS patients has not been extensive due
to limited material, but interestingly all
cancers have been reported to LOH of
LKB1 (Entius et al., 2001; Su et al., 1999).
This could suggest that while polyps may
arise in heterozygous state, cancer
development requires biallelic inactivation
of LKB1
3.4 LKB1 Mutations in
Sporadic Cancers
Hundreds of sporadic tumors and cell
lines have been studied to evaluate the
role of LKB1 mutations in sporadic
tumorigenesis. Although chromosomal
loss at 19p13.3 is commonly observed in
cancers only limited numbers of somatic
mutations in the remaining LKB1 allele
have been demonstrated. Colorectal
cancer is among the most extensively
studied tumor type. Most studies have
shown that biallelic inactivation of LKB1
is rare in colorectal carcinomas
(Avizienyte et al., 1998; Launonen et al.,
2000; Nakagawa et al., 1999; Resta et al.,
1998; Wang et al., 1998). A notable
exception to this is the high frequency of
LOH with accompanying missense
mutations in the remaining allele in
Korean patients with left sided colon
cancer (Dong et al., 1998). However, in
more detailed analysis 6 of 7 mutations
were shown not to disrupt Lkb1
autocatalytic activity (Launonen et al.,
2000).
Biallelic mutations have not been
demonstrated in breast cancer, CNS
tumors, adenoma malignum and SCTAT
tumors (Bignell et al., 1998; Connolly et
al., 2000; Forster et al., 2000; Sobottka et
al., 2000). However, a few cases of
biallelic LKB1 mutations have been
described in lung adenocarcinoma,
ovarian cancer and melanoma (Avizienyte
et al., 1999; Rowan et al., 1999; Wang et
al., 1999). In 5% of sporadic pancreatic
and biliary adenocarcinomas truncating
mutations in the remaining LKB1 allele
are accompanied with LOH (Su et al.,
1999), arguing that somatic LKB1
mutations might have a role in the
development of pancreatic and biliary
cancers.
Since somatic mutations in sporadic
cancers have been relatively rare, it has
been suggested that alternative
mechanisms may be important for
nactivating LKB1. This has been
supported by demonstrating LKB1
promoter methylation and mRNA down
regulation in primary tumors and cell lines
(Esteller et al., 2000; Tiainen et al., 1999;
Trojan et al., 2000).
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Type of Mutation Figure Origin of Mutation Reference
wild type
Y49D melanoma cell line Rowan A et al. 1999
Y60X PJS Olschwang S et al. 2001
L67P PJS Hemminki A et al. 1998
Q100X PJS Westerman AM et al. 1999
K108R PJS Wang ZJ et al.  1999
Y118X PJS Olschwang S et al. 2001
C132X PJS Olschwang S et al. 2001
G135R melanoma Rowan A et al. 1999
F157S PJS Ylikorkala A et al. 1999
D162N PJS Westerman AM et al. 1999
G163D PJS Westerman AM et al. 1999
G163D testicular cancer Avizienyte E et al. 1998.
L164M PJS Westerman AM et al. 1999
G171S colorectal cancer Dong SM et al. 1998
D176N PJS Mehenni H et al.1998
N181Y PJS Ylikorkala A et al. 1999
L182P PJS Olschwang S et al. 2001
D194N PJS Westerman AM et al. 1999
D194V lung cancer Avizienyte E et al. 1999
D194Y melanoma Guldberg P et al.1999
E199K colorectal cancer Dong SM et al. 1998
D208N colorectal cancer Dong SM et al. 1998
G215D colorectal cancer Dong SM et al. 1998
S232P PJS Yoon KA et al. 2000
G242W PJS Olschwang S et.al 2001
G242V PJS Olschwang S et al. 2001
G251S PJS Resta N et al. 1999
E256S PJS Yoon KA et al. 2000
H272Y PJS Boardman LA et al. 2000
P281L ovarian cancer Nishioka Y et al. 1999
P281L colorectal cancer Dong SM et al. 1998
R297K PJS Westerman AM et al. 1999
R297S PJS Boardman LA et al. 2000
R304W PJS Resta N et al. 1999
W308C PJS Mehenni H et al.1998
P314H colorectal cancer Resta N et al. 1999
P324L gastric carcinoma Park WS et al. 1998
P324L PJS Yoon KA et al. 2000
F354L colorectal cancer Dong SM et al. 1998
T367M colorectal cancer Dong SM et al. 1998
D51-56 PJS Mehenni H et al.1998
D52 PJS Olschwang S et al. 2001
D107-109 PJS Wang ZJ et al.1999
D137-140 PJS Ylikorkala A et al. 1999
D175-176 PJS Resta N et al. 1999
D247 PJS Nakagawa H et al. 1998
D303-306 PJS Hemminki A et al. 1998
D330-334 PJS Gruber SB et al. 1998
D98-155 PJS Hemminki A et al. 1998
D156-307 PJS Jenne et al.1998
416 stop PJS Wang ZJ et al.1999
frameshift 359 PJS Westerman AM et al. 1999
frameshift 342 PJS Yoon KA et al. 2000
frameshift 319 PJS Olschwang S et.al 2001
frameshift 316 PJS Westerman AM et al. 1999
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frameshift 312 Pancreatic cancer Su et al. 1999
308 stop PJS Ylikorkala A et al. 1999
frameshift 307 PJS Hemminki A et al. 1998
Frameshift 306 PJS Westerman AM et al. 1999
Frameshift 305 PJS Ylikorkala A et al. 1999
Frameshift 302 PJS Mehenni H et al.1998
Figure 1.Small mutations reported in PJS patients, sporadic cancers and cell lines
High frequency of mutations in the kinase domain (grey).
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4. LKB1 Gene is Predicted
to Encode a
Serine/Threonine Kinase
The characteristic feature of
serine/threonine kinases is a catalytic
kinase domain composed of eleven
subdomains. The kinase domain binds
substrate proteins and ATP in the presence
of a divalent cation (Mg2+, Mn2+), and
transfers the g -phosphate group of the
ATP to a serine or threonine residue of the
substrate. Hundreds of serine/threonine
kinases have been identified in
eukaryotes, the majority of which are
implicated in signal transduction.
Typically, kinases form cascades
phosphorylating their target proteins to
achieve amplified signal with high
specificity. As a result, extracellular
signals (such as growth factors and
hormones), nutritional and enviromental
stress signals, and cell cycle checkpoints
are translated into coordinated
transcriptional responses in the nucleus.
Serine/threonine kinases are
subdivided into major groups based on the
degree of homology in the kinase domain
(Hanks et al., 1988). Lkb1 is placed into
the calmodulin dependent kinase (CaMK)
group, where it exhibits weak homology
to AMP activated protein kinase (AMPK).
AMPK is composed of a catalytic subunit
and two regulatory subunits (Beri et al.,
1994; Carling et al., 1994) and it is
activated allosterically by elevated AMP
levels during metabolic stress (Ferrer et
al., 1985; Harwood et al., 1984).
4.1 Lkb1 Kinase in Other
Species
The conservation of genes and their
function between species allows scientists
to use others species as model organisms
to study the function of genes in vivo.
Model organisms have been used
successfully to identify novel pathways
that control cell growth, differentiation
and programmed cell death.
Lkb1 kinase has been highly conserved
during evolution and some information is
available on Lkb1 homologues in mice,
Xenopus, and C.elegans. The Drosophila
homologue has been identified only by
sequence. Smith et al. characterized the
mouse Lkb1, and found it to be localized
on mouse chromosome 10. The genomic
structure of mouse Lkb1 is similar to the
human LKB1 consisting of ten exons
(Smith et al., 1999). The human and
mouse Lkb1 proteins share 96.2% identity
in the kinase domain and 89.7% identity
overall.
The Xenopus Lkb1, termed Xeek1, was
identified in a screen to identify novel
kinases homologous to cell cycle kinase
Cdc2 (Su et al., 1996). In fact, Xeek1 was
the first Lkb1 kinase family member to be
identified and it was identified well before
LKB1 was linked to the Peutz-Jeghers
syndrome. Human Lkb1 and Xeek1 share
93% identity in the kinase domain and
82% overall identity (Jenne et al., 1998).
XEEK1 has been shown to co-
immunoprecipitate and phosphorylate an
unknown 155 kDa protein. Moreover, the
XEEK1 C-terminus is phosphorylated by
PKA, but the significance of this
modification is unknown.
A kinase (Par-4) homologous to Lkb1
was identified from nematode C.elegans.
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Par-4, along with five other Par genes
(Par-1 to Par-6), were required for cell
polarization and asymmetric cleavage in
C.elegans embryos (Kemphues et al.,
1988; Watts et al., 1996). Par-4 gene was
subsequently cloned and shown to encode
a serine/threonine kinase homologous to
Lkb1 and Xeek1 (Watts et al., 2000). The
sub-cellular distribution of Par-3/Par-6
protein complex was altered in Par-2, Par-
4 and Par-5 mutant embryos, thus
establishing a genetic link between these
genes (Hung and Kemphues, 1999).
Recently, mammalian homologues have
been identified for Par-3 and Par-6 (Izumi
et al., 1998), and they have been shown to
form a functional unit with atypical
protein kinase C and cdc42 or Rac1 that
c ntrol cell polarity (Johansson et al.,
2000; Lin et al., 2000; Qiu et al., 2000).
This suggests that Par genes form a
pathway that may be functionally
conserved from nematodes to man.
Figure 2. Relationship of Lkb1 to other kinases
Lkb1 kinases are conserved during evolution. The human Lkb1 has homologues in
Mouse (Lkb1), Xenopus (Xeek1), Drosophila (dLkb1) and C.elegans (Par-4). The
closest Lkb1 relative in humans is the AMP activated kinase (AMPK), which belongs to
the CAM kinase group. However, AMPK shares more homology with the SNF-1 stress
kinase in yeast demonstrating that Lkb1 kinases are a distinct kinase group.
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AIMS OF THE STUDY
Mutations in LKB1 serine/threonine kinase gene are found in Peutz-Jeghers syndrome
patients, but the functions of Lkb1 kinase and how LKB1 mutations predispose to cancer is
not known.
1. Characterize the protein encoded by the LKB1 g ne including generation of a functional
assay.
2. Study the functional consequences of LKB1mutations with the functional assay.
3. Explore Lkb1 expression and function in tumor cell lines
4. Study the functional effects of reintroduction of Lkb1 into tumor cell line
5. Study the expression patterns of the Lkb1 and Pten tumor suppressor genes during mouse
development.
6. Study functions of Lkb1 in vivo by creating mice lacking Lkb1.
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MATERIALS AND
METHDOS
Detailed description of materials and
methods are in original publications.
cDNA Sequencing (Study I)
RNA was converted to cDNA in RT
reaction using random priming method
with M-MLV reverse transcriptase and
RNase inhibitor. The coding region of
LKB1 was amplified by standard PCR
protocol.
Exon Sequencing (Study I)
33 PJS patients were available for the
mutation screening in LKB1. The
diagnosis was based on the presence of
histopathologically confirmed intestinal
Peutz-Jeghers polyposis. Other clinical
data, such as information on
mucocutaneous pigmentation, and clinical
features of family members were not
available for all patients. Of the 33
patients, 20 had a family history of PJS
and 8 were sporadic. In 5 cases family
data was not available. Mucocutaneous
pigmentation was documented in almost
all cases (17 of 18) where the information
about the pigmentation was available.
Isolation of DNA was performed using
standard procedures and EBV-
immortalized cell lines were prepared
from PJS patients' blood samples using
standard methods. Mutation screening was
performed by genomic sequencing of the
nine coding LKB1 exons. Primers were
designed to cover all exonic coding
sequences as well as splice acceptor and
donor sites.
Genotype and Linkage
Analysis (Study I)
Microsatellite markers D19S180,
D19S880, D19S891 and D19S254 were
used to test for linkage to 19q13.4 in six
families negative for LKB1 germline
mutation. Multipoint linkage analyses
were performed using the program
GENEHUNTER. Marker allele sizes and
frequencies were obtained from Centre
d´Etudes du Polymorphisme Humain
(CEPH; http://www.cephb.fr) and from
the Genome Database
(http://gdbwww.gdb.org). A dominant
mode of inheritance with 85% penetrance
was assumed. The disease allele frequency
was set to 0.0002.
Southern Blotting (Study I)
8 µg of genomic DNA was digested
with EcoRI and TaqI restriction enzymes,
resolved by 0.8% agarose gel
electrophoresis and blotted onto
membrane. The probes were PCR
amplified from the LKB1 cDNA and
genomic DNA. Hybridizations were
carried out using standard protocols.
LKB1 Expression Constructs
(Study I)
The coding region of wild type or
mutant LKB1 was PCR amplified and the
PCR fragment was digested and subcloned
into EcoRI and SalI sites of pCI-Neo
based vectors containing N-terminal
hemagglutinin (HA) or Myc epitope tags.
All LKB1 alleles were confirmed by
sequencing.
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Cell Culture and
Transfections (Study I, II)
G361 (melanoma), HeLa S3 (cervical
carcinoma), SW480 (colorectal
adenocarcinoma), U2OS (osteosarcoma),
and NIH3T3 (fibroblast) cells were grown
in DMEM with 10% FCS, L-glutamine,
and penicillin/streptomycin. The cells
were transfected using the calcium
phosphate transfection method. For
determining the colony forming ability,
the transfected cells were subjected to 2-3
mg/ml G418 selection for 16 to 20 days.
For counting, the colonies were fixed with
5% trichloroacetic acid and stained with
3% Giemsa stain.
Metabolic Labeling of
Cellular Proteins (Study I)
48 hours after transfection cells were
starved for 1 hour in media lacking
cysteine and methionine followed by a
metabolic labeling with 200 µCi/ml of a
mixture of S35cysteine and
S35methionine for 2 hours. Subsequently
cells were lysed and subjected to
immunoprecipitation. Immunoprecipitates
were washed and subjected to SDS-PAGE
analysis followed by fluorography.
Immunoprecipitation and
Kinase Assays (Study I, II)
48 h after transfection cells were
collected and lysed followed by an
overnight immunoprecipitation with
12CA5 anti-HA, 9E10 anti-myc or a
specific polyclonal antiserum raised
against a 15 amino acid C-terminal
peptide of human Lkb1. Control
immunoprecipitations were performed
with anti-Lkb1 preincubated with the
antigenic peptide. Subsequently
immunoprecipitates were washed and
incubated at 30oC for 30 min in kinase
buffer containing 10 µCi of P32g ATP.
The reactions were stopped by adding
boiling SDS-PAGE sample buffer and
analyzed on 10% SDS-PAGE gel.
Northern Blotting (StudyII)
Clontech Multiple Tissue Northern
(MTNTM) Blot (#7757-1) was hybridized
according to standard protocols.
Western Blotting (Study
I, II, IV)
20 µg-40 µg of protein from cell
lysates were analyzed by SDS-PAGE and
western blotting according to standard
techniques using anti-HA, anti-Myc,
polyclonal anti-Lkb1 or anti-Glut-1
antibodies and detected by enhanced
chemiluminescence.
Immunofluorescence
(Study II)
Cells were seeded on coverslips and
fixed with 3.5% paraformaldehyde 48
hours post-transfection. Double
immunofluorescence was performed with
polyclonal anti-Lkb1 and monoclonal
anti-ß-galactosidase, which were detected
with rhodamin-conjugated anti-rabbit and
fluorescein-conjugated anti-mouse
secondary antibody, respectively. The
nuclei were visualized with Hoechst
33342.
Flow Cytometry Analysis
(Study II)
G361 cells were co-transfected with
LKB1 plasmids and pCMV/CD20
selection plasmid. The cells were treated
with nocodazole to induce a G2/M phase
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block. Subsequently cells were detached,
incubated with anti-CD20-FITC and fixed
with 80% ethanol. Propidium iodide was
used to stain the nuclei. The cell cycle
distribution of CD20 positive and negative
cells was analyzed with a Coulter EPICS
flow cytometer. Percentages of cells in
G1, S and G2/M phases were determined
with CellFIT cell cycle analysis program.
Lkb1 Deficient Mice
(Study IV)
Two independent targeting strategies
were used. The first (figure 3) resulted in a
deletion of genomic sequences
encompassing exons 2 to 7 (of 10 total);
the second (figure 4), based on Cre/LoxP
methodology, resulted in the inversion of
these sequences. In both cases, we used a
6.3 kb NsiI-HindIII (5') fragment and 2.0
kb BamHI-BamHI (3') fragment of
genomic sequence. Positive (PGK-
Neomycin) and negative (PGK-HSV-tk)
election markers were used in both
strategies. The target vectors were
lectroporated into ES cells and correctly
targeted clones were identified by
Southern blotting with 5' and 3' external
probes. ES cell clones were injected into
C57BL/6 blastocysts. Several chimeric
offspring were found to transmit targeted
alleles in the germline. Germline
inactivation of Lkb1 utilizing the
LoxP/Cre-technique was achieved by
crossing targeted animals to PGK-Cre
mice (Lallemand et al., 1998). Stable
inversion of the targeted sequences was
then achieved by breeding the PGK-Cre
transgene out of subsequent generations.
Lkb1-/- animals obtained with both
strategies were found to have identical
phenotypes and both were used in this
study.
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Figure 3.
Targeting strategy designed to replace exons 2-7 of the mouse Lkb1 locus by PGK-Neo
cassette.
Figure 4.
Cre-recombinase mediated targeting strategy designed to place Lox-P sites in 1st and 7th
introns. Lox-P sites result in the inversion of the exons 2-7 and creation of non-
functional allele in the presence of Cre recombinase.
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Embryo Cultures (Study IV)
E9.5 embryos were minced and
cultured on 48-well plates in DMEM
containing 15% FCS. For the VEGF
analysis, 25,000 MEFs from individual
embryos in passage 3 were plated on 24-
well plates and cultured in normoxic (21%
O2) or hypoxic (1% O2) conditions for 24
hours. Conditioned medium was removed
and VEGF concentration was analyzed by
ELISA. Remaining cells were lysed
immediately in SDS sample buffer, and
subjected to SDS-PAGE analysis.
TUNEL Labeling (Study IV)
Paraformaldehyde-fixed and paraffin-
embedded 7-µm tissue sections were used
to study cell death in embryonic tissues.
Terminal deoxytransferase-mediated
deoxy-uridine nick end-labeling (TUNEL)
analysis was performed according to
manufacturer´s instructions and
counterstained with Hoechst 33342.
In situ Hybridization (Study
III, IV)
A mouse Lkb1 open reading frame in
pGEM-T or a PCR fragment of human
PTEN (96% identity to mouse sequence)
open reading frame were used for in vitro
transcription of 
35
S-UTP-labeled antisense
and sense probes. In situ hybridizations
were performed according to Wilkinson
and Green (Wilkinson et al., 1990) with
modifications (Luukko et al., 1996). The
probes for Vegf, flk-1, flt-1 are described
previously (Kaipainen et al., 1993).
Whole-mount in situ
Hybridization (Study IV)
Embryos were fixed in 4%
paraformaldehyde, bleached in 7% H2O2-
93% methanol, treated with proteinase K
and post-fixed in 4%
paraformaldehyde/0,2% glutaraldehyde.
Hybridization with digoxygenin-UTP-
labeled antisense probe was followed by
RNaseA/RNaseT1 treatment. Embryos
were incubated with alkaline phosphatase
conjugated anti-digoxigenin antibody.
Whole-mount
Immunostainings (Study IV)
Embryos were fixed in 4%
paraformaldehyde, bleached in 5% H2O2-
95% methanol and blocked. After
incubation with antibodies against CD31
and smooth muscle actin the embryos
were treated with peroxidase-conjugated
secondary antibodies and developed in
3,3'-diaminobenzidine (DAB).
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RESULTS AND
DISCUSSON
The Prevalence of LKB1
Mutations in PJS (Study I)
To investigate the prevalence and
nature of germline mutations in PJS
families and in non-familial PJS cases, we
performed germline mutation analyses of
LKB1 in 33 unrelated PJS patients.
In direct genomic sequencing 18
different mutations were detected. Fifteen
mutations compromised the LKB1 open
reading frame, and involved small
truncations and point mutations, and three
changed splice donor or acceptor sites.
Samples which did not exhibit mutations
in genomic sequencing were subsequently
scrutinized for large genomic
rearrangements by RT-PCR or Southern
blotting analysis. Southern analysis of
genomic DNA revealed aberrant bands
suggesting that an approximately 2 Kb
deletion may have occurred in one LKB1
allele in one sample.
The prevalence of observed LKB1
mutations in familial cases was 12/20
(60%), and 4/8 in sporadic cases (50%). In
the whole series 19 (58%) mutations in
LKB1 were observed in 33 PJS patients.
The proportion of mutation-positive PJS
individuals in our study was significantly
lower than in the initial reports (Gruber et
al., 1998; Hemminki et al., 1998; Jenne et
al., 1998), but it is in accordance with
recent reports with more material. This
suggests that a second PJS locus might
exist (Mehenni et al., 1998; Nakagawa et
al., 1998; Olschwang et al., 2001; Resta et
al., 1998; Wang et al., 1999; Westerman et
al., 1999; Ylikorkala et al., 1999).
Linkage to 19q13.4 (Study I)
In our series, 10 mutation-negative
patients failed to demonstrate linkage to
19p13.3. To study linkage to the possible
minor PJS locus in 19q13.4 (Mehenni et
al., 1997), we used microsatellite markers
D19S180, D19S880, D19S891 and
D19S254 in 6 families where no LKB1
genetic defect or linkage to 19p13.3 was
found. LOD scores ranging from –10.16
to 0.54 with these markers suggested no
linkage to 19q13.4, excluding it as an
alternative locus among these patients.
LKB1 Gene Encodes a
Protein Kinase (Study I)
To characterize the protein encoded by
LKB1, we cloned the LKB1 open reading
frame (ORF) into a mammalian
expression vector and transiently
expressed HA-epitope-tagged Lkb1 in the
human osteosarcoma cell line U2OS.
Cells were metabolically labeled using
S35cysteine and S35methionine and
analyzed on SDS-PAGE. Lkb1 protein
was observed to migrate at 60 kDa, which
is higher than its predicted molecular
weight (48 kDa). This suggests that Lkb1
protein could be covalently modified in
vivo.
To study the catalytic activity of Lkb1,
HA-tagged Lkb1 was immunoprecipitated
from cellular lysates an in vitro kinase was
carried out. In contrast to the Lkb1
homologue in Xenopus, which did not
exhibit autocatalytic activity, a prominent
phosphorylated band was noted at 60 kDa
in Lkb1 immunoprecipitates. This band
was presumed to represent Lkb1
autophosphorylation. Alternatively, the
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immunoprecipitates could contain another
kinase capable of phosphorylating Lkb1.
Moreover, a 115 kDa protein was
observed to co-immunoprecipitate with
Lkb1 in S35 labeled lysates. This band
could represent an endogenous Lkb1
interacting protein or a substrate.
However, phosphorylation of this 115 kDa
protein was not observed.
Mutations in PJS Patients
Impair Lkb1 Activity
By measuring Lkb1 kinase activity we
compared wild type Lkb1 to three mutants
with minor predicted changes identified in
Peutz-Jeghers syndrome. The mutants
used included a C-terminal truncation
(308 stop), 4 amino acid in-frame deletion
(D 303-306) and a one amino acid
substitution (L67P) (Figure 1). PJS-
associated mutations encoded a stabile
Lkb1 protein, but in contrast to the wild
type, the PJS-mutatnts did not exhibit
detectable kinase activity. Furthermore, a
sporadic testicular cancer-derived
mutation (G163D) was included in the
studies (Figure 1). In contrast to the
undetectable activity in the PJS-derived
mutations, the testicular cancer-derived
mutant had retained small amount of
activity, although it was significantly
reduced compared to the wild-type Lkb1.
These results demonstrated that PJS- and
cancer-derived mutations inactivate or
severely compromise Lkb1 kinase
activity.
The Subcellular Localization
of Lkb1 (Study II)
The subcellular localization of Lkb1
was studied in G361 cells transiently
transfected with LKB1 expression
constructs by immunofluoresence
analysis. Lkb1 was detected
predominantly in the nucleus, but in a
significant fraction (ca. 30%) of cells,
Lkb1 was found mainly in the cytoplasm.
Similar Lkb1 localization pattern has been
reported by other groups (Collins et al.,
2000; Nezu et al., 1999). In addition to
nuclear and cytoplasmic localization,
Lkb1 has been demonstrated to associate
with plasma membrane (Collins et al.
2000; Sapkota at al., 2001). The distinct
distribution of Lkb1 in the cells may
suggest that Lkb1 function is regulated by
altering its subcellular localization.
Interestingly, Nezu et al. have proposed
that Lkb1 may be inactivated by nuclear
sequestration; thus, these authors have
demonstrated full autocatalytic activity,
but exclusively nuclear localization, of the
(D 303-306) deletion (Nezu et al., 1999).
However, other groups, including ours,
have not been able to demonstrate
measurable kinase activity in the D 303-
306 mutant (Marignani et al., 2001). In
fact, our results suggest that nuclear
localization is a common feature of all
catalytically inactive Lkb1 alleles,
including D 303-306 (Tiainen et al.,
unpublished).
In addition to the Lkb1 kinase activity
the nuclear localization requires a nuclear
localization signal sequence (NLS)
localized on the N-terminus of Lkb1
(Smith et al., 1999).
LKB1 mRNA Expression
and Activity in Tumor
Cells (Study II)
In order to study LKB1 mRNA
expression in human tumors, we
performed northern blotting analysis on a
panel of human tumor cell lines
originating from various tissues. HeLa S3
cells (cervical adenocarcinoma) had
undetectable, and G361 cells (melanoma)
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exhibited severely reduced levels of LKB1
mRNA, suggesting that mRNA
downregulation could be a mechanism to
impair Lkb1 function in human tumors.
We also analyzed Lkb1 activity in
HeLa S3 and G361 cell lines by
immunoprecipitating Lkb1 with a specific
polyclonal antiserum followed by in vitro
kinase assay. Lkb1 activity was
undetectable in HeLa S3 cells, and
markedly reduced in G361 cells, in
accordance to their LKB1 mRNA levels.
Thus, measuring endogenous Lkb1 kinase
activity provides a method to assess the
function of Lkb1 in tumors and to detect
LKB1 gene inactivation.
Lkb1 Induces Cell Cycle
Arrest (Study II)
To investigate the possibility that
LKB1 mRNA and kinase activity
downregulation in HeLa S3 and G361
provides a growth advantage to these
cells. G361 and HeLa S3 cells were
transfected with an expression vector
encoding both Lkb1 and a neomycin
resistance gene, or a vector encoding the
selection marker only. The transfections
were subsequently subjected to G418
selection. A strongly reduced number of
colonies was detected in LKB1
transfections compared to the vector-only
transfections in both G361 and HeLa S3
cells, indicating that re-expression of
Lkb1 resulted in growth suppression in
these cells.
The growth suppression by ectopic
Lkb1 was limited to cells with
undetectable or low endogenous levels of
Lkb1 (such as G361 and HeLa S3 cells).
Thus, cells resistant to growth inhibition
by ectopic Lkb1 may have acquired
mutations, which prohibit suppression by
Lkb1. Alternatively, a regulatory subunit
might be needed for full Lkb1 activity.
We also investigated whether Lkb1
kinase activity was necessary for growth
inhibition and took advantage of three
LKB1 mutant alleles (D 303-306, 308 stop
and G163D) that impair Lkb1 kinase
activity. All three naturally occurring
mutant LKB1 alleles were unable to
suppress growth of G361 cells. Indicating
that Lkb1 kinase activity is required for
the growth suppression.
The cell cycle changes in G361 cells
transfected with either wild-type or mutant
Lkb1 were studied using flow cytometry
(FACS). Proliferating cells were arrested
in mitosis with the microtubule-stabilizing
agent nocodazole to reveal cells blocked
in G1. The G1 fraction of wild-type LKB1
transfected cells was 36% compared to
18% of D 303-306 mutant transfected cells,
indicating that LKB1 growth suppression
result from G1 cell cycle arrest. The
observation that Lkb1 induces cell cycle
arrest provides evidence that LKB1 umor
uppressor has a gatekeeper function.
The mechanism of the LKB1-mediated
cell cycle arrest has been further studied
by Marignani et al., who has demonstrated
that Lkb1 protein associates with Brg1
chromatin remodeling protein and
stimulates its ATPase activity n vitro.
However, the increase in Brg1 ATPase
activity was not dependent on Lkb1 kinase
activity, since the inactive D 303-306
mutant was also capable of increasing
Brg1 activity. On the other hand, the
Brg1-dependent growth arrest and flat cell
morphology was shown to require Lkb1
kinase activity. This controversy might
suggests that Lkb1 kinase activity may not
be mediating all Lkb1 functions
(Marignani et al., 2001).
In addition to cell cycle control, it has
been suggested that Lkb1 might have role
in programmed cell death. Karuman et al.
have demonstrated that Lkb1 and p53
proteins interact and that Lkb1
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translocates into mitochondria followed
by apoptotic stimulus. Moreover,
expression of a C-terminal truncation of
Lkb1 was capable of inducing a p53-
dependent cell death (Karuman et al.,
2001). However, similar C-terminal
truncations have been reported in cancer
prone PJS patients (Figure 1), arguing that
these mechanisms do not provide
explanation for the increased cancer risk
in PJS. Despite this controversy, other
groups have also connected Lkb1 to p53
by demonstrating that Lkb1
phosphorylates p53 in vitro (Sapkota et
al., 2001, Vaahtomeri et al. unpublished).
Similar to the Xenopus Lkb1 (Xeek1),
mammalian Lkb1 contains a cAMP-
dependent protein kinase A (PKA)
consensus phosphorylation site (serine
431) on its C-terminus. This site has been
shown to be phosphorylated by p90
ribosomal S6 kinase (p90RSK) and (PKA)
in vivo. The functional relevance of this
modification was studied by showing that
a mutant lacking this phosphorylation site
(S431A) was not able to suppress G361
melanoma cell growth. Interestingly, the
S431A allele retains full kinase activity,
thus separating Lkb1 kinase activity and
growth suppression (Sapkota et al., 2001).
The C-terminus of Lkb1 has been
reported to contain a prenylation sequence
that is actively farnesylated in vivo. The
functional relevance of this modification
is still unclear. Abrogation of this motif
did not alter the localization, activity or
growth suppressive properties of Lkb1
(Collins et al., 2000; Sapkota et al., 2001).
Moreover, a putative PKB/Akt
phosphorylation site at threonine 336 has
also been identified in the Lkb1 C-
terminus (Sapkota et al., 2001) and the
role of this potential regulatory element is
currently under evaluation.
Expression of Lkb1 and
Pten During Mouse
Development (Study III)
Peutz-Jeghers syndrome (PJS) and
Cowden disease (CD) are conditions that
share some clinical features, such as
hamartomatous polyposis and increased
risk of cancer. Due to the similarities of
PJS and CD, PTEN and LKB1 could
function in the same cells and in the same
signaling pathway. To analyze potential
co-localization of PTEN and LKB1 and
their possible roles in embryonic
development, we studied their expression
during mouse embryonic development by
RNA in situ hybridization.
Hybridization of Lkb1 and Pten probes
to embryonic day 7 – 11 (E7.0-E11.0)
embryos revealed a high ubiquitous
expression of both mRNAs in all
extraembryonic and embryonic tissues. In
later stages of development, the
expression of both P en and Lkb1 became
more pronounced in lung epithelium and
mesenchyme, thyroid gland, thymus,
salivary gland, kidney epithelium and
urinary bladder epithelium. The
embryonic liver contained relatively more
Lkb1 than Pten expression.
In the gastrointestinal tract, Lkb1 and
Pten signal was detected from the early
stages of development. Later, an intense
expression became restricted to the
mucosal epithelium of the small intestine,
colon and rectum. Both transcripts were
also seen in the epithelium of the oral
cavity, esophagus and stomach.
In the E15.0 embryo, the central
nervous system (CNS) had relatively more
expression of Pten, but later prominent
expression of both genes was observed in
the (CNS) and in peripheral nerve ganglia.
Lkb1 and Pten mRNAs were also present
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at high levels in the epithelium lining the
nasal cavity.
Additionally, intense Lkb1 expression
was noted in seminiferous tubules of the
testis containing spermatogonia and
Sertoli cells.
In summary, expression of Lkb1 and
Pten mRNA were observed in tissues and
organs affected in Peutz-Jeghers
syndrome and Cowden disease. In
addition, similar expression patterns of
Lkb1 and Pten suggests that these genes
may interact functionally during
embryonic development.
In later studies, similar LKB1 mRNA
expression pattern has been reported in
human fetal tissues. In adult human and
mouse tissues high LKB1 expression has
been detected in testis, esophagus, and in
crypts of the colonic villi (Rowan et al.
2000; Luukko et al. unpublished).
Mice Lacking Lkb1 Die
During Midgestation (Study
IV)
To study the function of Lkb1 in vivo,
we generated Lkb1-deficient mice by
introducing an inactivating Lkb1 allele
into murine embryonic stem (ES) cells by
homologous recombination (F g3, 4).
In intercrosses of Lkb1 heterozygous
(Lkb1+/-) mice, both Lkb1+/+ (n=87) and
Lkb1+/- (n=177) animals were observed at
expected frequencies, while no Lkb1-/-
animals were obtained, demonstrating that
Lkb1-/- mice die during development.
Analysis of Lkb1-/- embryos throughout
embryonic development revealed no
abnormalities prior to embryonic day 7.5
(E7.5), and the majority of embryos
appeared to develop normally up to E8.0.
Macroscopic analysis of Lkb1-/-
embryos beyond E8.25 revealed multiple
abnormalities, including a failure of the
embryo to turn, a defect in neural tube
closure, and a hypoplastic or absent first
branchial arch.
Whole-mount in situ hybridization was
used to study the integrity of various
developmental lineages in the Lkb1-/-
embryos at E8.5 and E9.5. The expression
of the mesodermal marker brachyury
showed that notochord developed
normally along the anterior/posterior axis
in the mutant embryos, but the defective
somites in Lkb1-/- embryos failed to
express Engrailed1 at E9.5. No
pronounced changes in the expression of
Wnt3A, Fgf8 or Krox-20 were noted,
suggesting that there was normal
development of the mesoderm of the tail
bud, forebrain and primitive streak, and
normal segmentation of the hindbrain. No
viable embryos were observed after E11.0,
indicating that Lkb1 is essential for
embryonic development.
Severe Vascular Defects in
Lkb1-/- Embryos (Study IV)
Mutant embryos at E9.25 had a
translucent appearance, suggesting the
possibility of vascular defects. The
embryonic vasculature was visualised by
PECAM-1 immunostaining. Both mutant
and wild-type embryos developed a paired
dorsal aorta at E8.5, but the mutant aorta
was thin and discontinuous particularly in
the anterior part of the vessel. At E9.5, the
lumen of the mutant aorta remained thin,
with intersomitic branches terminating
prematurely in the mesenchyme.
Abnormalities were also observed in
vascular smooth muscle cells (VSMCs) in
E9.5 embryos. Lkb1-/- embryos showed a
complete absence of VSMC staining in
the dorsal aorta and somites. In addition,
an unusual, strong ectopic smooth muscle
actin signal was detected in head folds of
mutant embryos, which did not appear to
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contribute to the supportive vascular
structures.
Apoptosis in Lkb1-/-
Embryos (Study IV)
Sections of E9.5 Lkb1-/- embryos often
revealed large cystic degenerations near
the dorsal aorta occasionally containing
embryonic blood cells. Additionally, the
surrounding cephalic mesenchyme had a
lower cell density and fewer developing
capillaries than controls. The decreased
cell density was due to increased cell
death in the mesenchyme as determined
by TUNEL. This phenotype was limited to
the E9.5 embryos; the E8.5 embryos
showed similar number of TUNEL
positive nuclei regardless of genotype
suggesting that the increased cell death in
the mesenchyme was secondary to the
vascular defects.
Vascular Defects in Lkb1-/-
Yolk Sacs and Placentas
(Study IV)
Analysis of extraembryonic tissues at
E9.5 revealed that the mutant yolk sacs
failed to develop large vitelline vessels
and an extensive capillary network.
Moreover, the vitelline artery was
completely atretic in Lkb1-/- yolk sacs,
effectively disconnecting the embryo from
the yolk sac (vitelline) circulation.
Mutant placentas at E9.5 were
oedematous, hemorrhagic, and small in
diameter and the invasion of embryonic
blood vessels into the placenta did not
occur in the mutant. In situ hybridizations
with a VEGF receptor probes (flk-1, flt-1),
confirmed the lack of fetal blood vessels
in the rudimentary labyrinth layer.
Deregulation of VEGF
Expression in Lkb1-/- Mice
(Study IV)
To investigate the mechanism
underlying the vascular defects we
analysed the expression of vascular
endothelial growth factor (VEGF), which
is a key regulator of embryonic vascular
development. VEGF mRNA was found to
be deregulated in both the embryonic and
extraembryonic compartments at E8.5 and
E9.5. The Lkb1-/- placentas exhibited
markedly diminished VEGF mRNA
expression particularly in the trophoblast
giant cells, whereas the Lkb1-/- embryos
expressed abnormally elevated levels of
VEGF in several tissues. This
demonstrated that Lkb1 can both
positively and negatively regulate VEGF
expression in a tissue-specific manner.
VHL is a component of a SCF-like E3
ubiquitin-protein ligase complex that
regulates VEGF expression by targeting
the Hypoxia Inducible Factor 1a (HIF-1a)
to proteosome-mediated degradation
(Maxwell et al., 1999; Cockman et al.,
2000; Ohh et al., 2000). Interestingly,
disruption of the murine VHL tumor
uppressor gene results in a similar down-
regulation of VEGF in the extraembryonic
tissues (Gnarra et al., 1997), while the
expression of VEGF in VHL-/- embryos
has not been reported. VHL loss in other
systems has been found to lead to up
regulation of VEGF (Mukhopadhyay et
al., 1997; Siemeister et al., 1996).
VEGF Expression in
Lkb1-/- MEFs (Study IV)
To study the VEFG expression in
individual cells wild-type and mutant
mouse embryonic fibroblasts (MEFs)
from littermate embryos were isolated and
subjected to hypoxia to induce VEGF
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expression. VEGF levels were measured
from the cell culture media by ELISA.
Analysis of VEGF levels in cell culture
media revealed that the mutant MEFs
produced significantly higher levels of
VEGF than controls in hypoxic conditions
demonstrating that Lkb1 regulates VEGF
expression.
To study the role of Lkb1 in hypoxia
responses we monitored the HIF-1
dependent induction of glucose transporter
1 (Glut1) in hypoxia. HIF-1 is a
transcription factor consisting of HIF-1a
and ARNT proteins forming a
heterodimeric complex to activate target
gene transcription (Wang et al., 1995;
Jiang et al., 1996; Wood et al., 1996). In
hypoxic conditions HIF-1 translocates into
nucleus and binds to the hypoxia
responsive elements (HRE) at promoters
and activates transcription of Glut1,
erythropoetin, VEGF and several enzymes
involved in the glycolytic pathway
(Semenza et al., 1994; Forsythe et al.,
1996; Kallio et al., 1998). Comparable
induction of Glut1 in wild-type and
mutant MEFs suggested that the HIF-1
pathway was intact in Lkb1mutant cells.
Moreover, VEGF secretion was increased
in normoxic conditions in the mutant
MEFs arguing that VEGF deregulation
was not hypoxia-dependent.
In order to explore the mechanism by
which Lkb1 regulates VEGF expression
we studied the activation of p42/44MAPK
and p38 kinases implicated in VEGF
regulation (Milanini et al., 1998; Pal et al.,
1997; Xiong et al., 2001). Comparable
l vels of activated p42/44MAPK and p38
kinases were observed in Lkb1 mutant and
wild-type MEFs suggesting that Lkb1
regulates VEGF expression by alternative
mechanisms.
These results show that loss of Lkb1
function leads to increased basal and
induced expression of VEGF in fibroblasts
thereby placing Lkb1 in the VEGF
signaling pathway.
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CONCLUDING
REMARKS
Cancer is a disease, which is
characterized by malignant transformation
and clonal expansion of cells. Tumor
suppressor genes and oncogenes control
this process. The LKB1 tumor suppressor
gene mutated in Peutz-Jeghers syndrome
encodes a serine/threonine kinase.
This work describes two separate
functions for the Lkb1 kinase. The
observation that Lkb1 activity induces cell
cycle arrest demonstrates that Lkb1 has a
gatekeeper function, suggesting that LKB1
mutations provide a growth advantage to
cells that promote transformation and
tumor development. On the other hand,
Lkb1 was shown to regulate VEGF
expression in Lkb1 deficient mice. This
surprising finding suggests that decreased
Lkb1 activity may convert cells to an
angiogenic state promoting the
recruitment of new bloodvessels into the
tumor.
Angiogenesis plays a key role in the
development of cancer and metastasis.
New blood vessels feed the expanding
tumor and provide a route for metastasis.
Large parts of the tumor are deprived of
oxygen due to an insufficient blood supply
(Helmlinger et al., 1997). This activates
the expression of genes that facilitate cells
to adapt to hypoxia. Thus, tumor switches
to an angiogenic state to meet the
metabolic needs of the rapidly growing
cells.
Besides direct growth control some
tumor suppressors regulate angiogenesis
by controlling the expression of
angiogenic mediators. The observation
that PTEN, VHL and p53 are able to
inactivate HIF-1, suggests that the HIF-1
transcription factor is crucial for the tumor
suppressor-mediated angiogenesis.
Consequently, inactivation of these tumor
suppressors result in the activation of HIF-
1 leading to sustained expression of
VEGF (Maxwell et al., 1999; Ravi et al.,
2000; Zundel et al., 2000). The
observation that HIF-1 mediated hypoxia
response, p42/44MAPK and p38 kinase
pathways were unaffected in Lkb1
deficient cells suggest, that Lkb1 may
regulate VEGF expression by an
alternative less well-characterized
mechanism. Studying the mechanism how
Lkb1 regulates VEGF levels may increase
our understanding on the angiogenesis
process and lead to novel therapies
targeting VEGF.
The study of Peutz-Jeghers syndrome
has been restrained due to the rarity of the
disease and limited material. Using Lkb1
heterozygous mice as a model for PJS
could circumvent this problem. In fact,
recent findings suggest that these mice
mimic the PJS-associated polyposis
providing a valuable tool to study the
Lkb1-dependent tumorigenesis in vivo.
These studies may provide insight on the
role of Lkb1-dependent cell cycle control
and VEGF deregulation in the
development of Peutz-Jeghers syndrome
and cancer.
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